Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  Issue: February 2021  |  February 16, 2021


Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.

References

  1. Bourne FM, Howell DA, Root HS. Renal and cerebral scleroderma. Can Med Assoc J. 1960 Apr 23;82(17):881–886.
  2. Moore HC, Sheehan HL. The kidney of scleroderma. Lancet. 1952 Jan 12;1(6698):68–70.
  3. Richardson JA. Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum. 1973 Mar-Apr;16(2):265–271.
  4. Cannon PJ, Hassar M, Case DB, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore). 1974 Jan;53(1):1–46. 
  5. Moorthy AV, Wu MJ, Beirne GJ, et al. Control of hypertension with acute renal failure in scleroderma without nephrectomy. Lancet. 1978 Mar11;1(8063):563–564. 
  6. Lopez-Ovejero JA, Saal SD, D’Angelo WA, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979 Jun 21;300(25):1417–1419.
  7. Bryan J. From snake venom to ACE inhibitor—the discovery and rise of captopril. Pharmaceutical Journal. 17 April 2009.
  8. Sealey JE. John H. Laragh, MD: Clinician-scientist. Am J Hypertens. 2014 Aug;27(8):1019–1023.
  9. Zawada ET Jr, Clements PJ, Furst DA, et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron. 1981;27(2):74–78.
  10. Whitman HH 3rd, Case DB, Laragh JH, et al. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum. 1982 Mar;25(3):241–248.
  11. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990 Sep 1;113(5):352–357.
  12. Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678–691. 
  13. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018 Sep;17(9):882–889.
  14. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000 Oct 17;133(8):600–603.
  15. Steen VD. Kidney involvement in systemic sclerosis. Presse Med. 2014 Oct;43(10 Pt 2):e305–314.
  16. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007 Jul;66(7):940–944. 
  17. Penn H, Quillinan N, Khan K, et al. Targeting the endothelin axis in scleroderma renal crisis: Rationale and feasibility. QJM. 2013 Sep;106(9):839–848.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

Related Articles
    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Can Technology Help Solve Scleroderma Renal Crisis?

    December 1, 2010

    A case study in using the Internet to facilitate rare disease research

    Case Report: A Patient Develops Scleroderma Renal Crisis

    October 18, 2019

    Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences